The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Fluorine in medicinal chemistry: A review of anti-cancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Fluorine in Medicinal Chemistry
Böhm, H., Banner, D., Bendels, S., Kansy, M., Kuhn, B., Müller, K., Obst‐Sander, U., & Stahl, M. (2004) · ChemBioChem · doi:10.1002/cbic.200301023 · Cited by 1,572
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications
Kirsch, P. (2004) · Cited by 700
Cyclooxygenase-2: A Therapeutic Target
Turini, M. E., & DuBois, R. N. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103952 · Cited by 683
Cyclooxygenase inhibitors – current status and future prospects
Dannhardt, G., & Kiefer, W. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01197-7 · Cited by 657
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Avril, N., Rosé, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., & Schwaiger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3495 · Cited by 557
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Orthogonal Multipolar Interactions in Structural Chemistry and Biology
Paulini, R., Müller, K., & Diederich, F. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462213 · Cited by 505
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Fluorine chemistry at the millennium
Dolbier, W. R. (2005) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2004.09.033 · Cited by 399
Important fluorinated drugs in experimental and clinical use
Ismail, F. M. D. (2002) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(02)00201-4 · Cited by 398
The discovery of the vinca alkaloids—chemotherapeutic agents against cancer
Noble, R. L. (1990) · Biochemistry and Cell Biology · doi:10.1139/o90-197 · Cited by 386
Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saitô, H., Okabe, H., Oyama, K., Takeda, S., et al. (1996) · PubMed · Cited by 370
Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Crystal structure and mechanism of a bacterial fluorinating enzyme
Dong, C., Huang, F., Deng, H., Schaffrath, C., Spencer, J. B., O'Hagan, D., & Naismith, J. H. (2004) · Nature · doi:10.1038/nature02280 · Cited by 335
Self-citationLaulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., & Davidson, B. S. (1999) · PubMed · Cited by 324
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
Multidrug Resistance Reversal Agents
Robert, J., & Jarry, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030183a · Cited by 292
Strategies for enzyme/prodrug cancer therapy.
Xu, G., & McLeod, H. L. (2001) · PubMed · Cited by 279
Ohtsu, H., Xiao, Z., Ishida, J., Nagai, M., Wang, H.-K., Itokawa, H., Su, C.-Y., Shih, C., Chiang, T., Chang, E., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020200g · Cited by 266
Radiohalogens for imaging and therapy
Adam, M. J., & Wilbur, D. S. (2005) · Chemical Society Reviews · doi:10.1039/b313872k · Cited by 260
Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
Hood, K. A., West, L. M., Rouwé, B., Northcote, P. T., Berridge, M. V., Wakefield, S. J., & Miller, J. H. (2002) · PubMed · Cited by 254
Taxol, a molecule for all seasons
Kingston, D. G. I. (2001) · Chemical Communications · doi:10.1039/b100070p · Cited by 233
DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
Zhao, X., Xu, C., Domagala, J., & Drlica, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13991 · Cited by 213
Cragg, G. M., & Newman, D. J. (2004) · Journal of Natural Products · doi:10.1021/np030420c · Cited by 210
Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., & Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12956 · Cited by 206
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Shao, W., & Brown, M. (2003) · Breast Cancer Research · doi:10.1186/bcr742 · Cited by 203
Protein Kinase Inhibitors as a Therapeutic Modality
Levitzki, A. (2003) · Accounts of Chemical Research · doi:10.1021/ar0201207 · Cited by 178
Use of aromatase inhibitors in breast carcinoma.
Santen, R. J., & Harvey, H. A. (1999) · Endocrine-related cancer · doi:10.1677/erc.0.0060075 · Cited by 165
Non-melanoma skin cancers and glucocorticoid therapy
Karagas, M. R., Cushing, G. L., Greenberg, E. R., Mott, L. A., Spencer, S. K., & Nierenberg, D. W. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1931 · Cited by 161
Olsen, J., Banner, D. W., Seiler, P., Wagner, B., Tschopp, T. B., Obst-Sander, U., Kansy, M., Müller, K., & Diederich, F. (2004) · ChemBioChem · doi:10.1002/cbic.200300907 · Cited by 160
Boumendjel, A., Baubichon-Cortay, H., Trompier, D., Perrotton, T., & Pietro, A. D. (2005) · Medicinal Research Reviews · doi:10.1002/med.20032 · Cited by 156
Thymidylate synthase and drug resistance
Peters, G. J., van der Wilt, C. L., van Triest, B., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00172-f · Cited by 155
Kubo, K., Shimizu, T., Ohyama, S.-I., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N. K., Takahashi, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030427r · Cited by 150
Adjuvant therapy of colon cancer
Macdonald, J. S. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.4.202 · Cited by 139
Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors
Harris, P. A., Cheung, M., Hunter, R., Brown, M. L., Veal, J. M., Nolte, R. T., Wang, L., Liu, W. J., Crosby, R. M., Johnson, J. H., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049538w · Cited by 137
Baures, P. W., Oza, V. B., Peterson, S., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00066-8 · Cited by 135
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Manallack, D. T., Hughes, R. A., & Thompson, P. E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040217u · Cited by 132
Farnesoid X Receptor: From Structure to Potential Clinical Applications
Pellicciari, R., Costantino, G., & Fiorucci, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0582221 · Cited by 129
The Prodrugs of 5-Fluorouracil
Malet‐Martino, M., Jolimaître, P., & Martino, R. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354146 · Cited by 128
Hashimoto, H., Imamura, K., Haruta, J., & Wakitani, K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010484p · Cited by 122
McCarty, M. F., Wey, J. S., Stoeltzing, O., Liu, W., Fan, F., Bucana, C. D., Mansfield, P. F., Ryan, A. J., & Ellis, L. M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1041.3.9 · Cited by 114
Fluorometabolite biosynthesis and the fluorinase from Streptomyces cattleya
Deng, H., O’Hagan, D., & Schaffrath, C. (2004) · Natural Product Reports · doi:10.1039/b415087m · Cited by 108
Self-citationBetageri, R., Zhang, Y., Zindell, R., Kuzmich, D., Kirrane, T. M., Bentzien, J., Cardozo, M. G., Capolino, A. J., Fadra, T. N., Nelson, R. M., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.025 · Cited by 106
Campos, S. M., Hamid, O., Seiden, M. V., Oza, A. M., Plante, M., Potkul, R. K., Lenehan, P. F., Kaldjian, E. P., Varterasian, M. L., Jordan, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.091 · Cited by 106
Mader, R. M., Müller, M., & Steger, G. G. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00191-8 · Cited by 104
(R)- and (S)-3-Fluorothalidomides: Isosteric Analogues of Thalidomide
Takéuchi, Y., Shiragami, T., Kimura, K., Suzuki, E., & Shibata, N. (1999) · Organic Letters · doi:10.1021/ol9902172 · Cited by 104
Li, L., Wang, H., Kuo, S., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00046a025 · Cited by 103
Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors
Manley, P. W., Furet, P., Bold, G., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020899q · Cited by 103
Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist
Fuhrmann, U., Hess‐Stumpp, H., Cleve, A., Neef, G., Schwede, W., Hoffmann, J., Fritzemeier, K., & Chwalisż, K. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001000c · Cited by 99
McLean, J. E., Neidhardt, E. A., Grossman, T. H., & Hedstrom, L. (2001) · Biochemistry · doi:10.1021/bi001810q · Cited by 97
Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template
Hunt, J. T., Mitt, T., Borzilleri, R. M., Gullo-Brown, J. L., Fargnoli, J., Fink, B. E., Han, W.-C., Mortillo, S., Vite, G. D., Wautlet, B. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049892u · Cited by 94
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Pourquier, P., Gioffre, C., Kohlhagen, G., Urasaki, Y., Goldwasser, F., Hertel, L. W., Yu, S., Pon, R. T., Gmeiner, W. H., & Pommier, Y. G. (2002) · PubMed · Cited by 93
Smaill, J. B., Showalter, H. D. H., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., Nelson, J. M., Sherwood, V., Vincent, P. W., Roberts, B. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000372i · Cited by 89
Fluorinase mediated C–18F bond formation, an enzymatic tool for PET labelling
Deng, H., Cobb, S. L., Gee, A. D., Lockhart, A., Martarello, L., McGlinchey, R. P., O’Hagan, D., & Onega, M. (2006) · Chemical Communications · doi:10.1039/b516861a · Cited by 86
Self-citationSignal Events: Cell Signal Transduction and Its Inhibition in Cancer
Rowinsky, E. K. (2003) · The Oncologist · doi:10.1634/theoncologist.8-suppl_3-5 · Cited by 86
Oral fluoropyrimidines in the treatment of colorectal cancer
Meropol, N. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00226-3 · Cited by 83
Favoni, R. E., & de Cupis, A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01446-7 · Cited by 83
Wang, S., Folkes, A. J., Chuckowree, I., Cockcroft, X. F., Sohal, S., Miller, W., Milton, J., Wren, S. P., Vicker, N., Depledge, P., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031011g · Cited by 80
Farnesyltransferase inhibitors: mechanism and applications
Rane, N. S., & Prendergast, G. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2105 · Cited by 78
Synthesis and Biological Activity of Sarcodictyins
Nicolaou, K. C., Kim, S., Pfefferkorn, J. A., Xu, J., Ohshima, T., Hosokawa, S., Vourloumis, D., & Li, T. (1998) · Angewandte Chemie International Edition · Cited by 70
Mauriac, L., Pippen, J., Albano, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00199-0 · Cited by 69
Recent Anticancer Cytotoxic Agents
Cozzi, P., Mongelli, N., & Suarato, A. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043482061 · Cited by 66
Liu, H., Liu, J., van Breemen, R. B., Thatcher, G. R. J., & Bolton, J. L. (2005) · Chemical Research in Toxicology · doi:10.1021/tx049776u · Cited by 66
Borzilleri, R. M., Zheng, X., Qian, L., Ellis, C. D., Cai, Z., Wautlet, B. S., Mortillo, S., Jeyaseelan, R., Kukral, D. W., Fura, A., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501275 · Cited by 65
Martarello, L., Schaffrath, C., Deng, H., Gee, A. D., Lockhart, A., & O’Hagan, D. (2003) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.779 · Cited by 64
Self-citationSelective oestrogen receptor modulators/new antioestrogens: a clinical perspective
Robertson, J. F. R. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.003 · Cited by 64
Kim, M.-Y., Duan, W., Gleason-Guzman, M. C., & Hurley, L. H. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0203377 · Cited by 62
Druker, B. J., O’Brien, S. G., Cortes, J., & Radich, J. (2002) · Hematology · doi:10.1182/asheducation-2002.1.111 · Cited by 62
Wissner, A., Floyd, M. B., Rabindran, S. K., Nilakantan, R., Greenberger, L. M., Shen, R., Wang, Y., & Tsou, H. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00598-x · Cited by 62
Honoré, S., Kamath, K., Braguer, D., Wilson, L., Briand, C. M., & Jordan, M. A. (2003) · PubMed · Cited by 61
Novel sulfonate analogues of combretastatin A-4
Gwaltney, S. L., Imade, H. M., Barr, K. J., Li, Q., Gehrke, L., Credo, R. B., Warner, R. B., Lee, J. Y., Kovar, P. J., Wang, J., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00098-1 · Cited by 54
Giannoukos, G., Szapary, D., Smith, C. L., Meeker, J. E. W., & Simons, S. S. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.2.0596 · Cited by 54
de Dios, A., Shih, C., de Uralde, B. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048978k · Cited by 52
Synthesis and biological evaluation of gemcitabine–lipid conjugate (NEO6002)
Ali, S. M., Khan, A. R., Ahmad, M. U., Chen, P., Sheikh, S., & Ahmad, I. N. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.046 · Cited by 52
Lepper, E. R., Ng, S. S. W., Gütschow, M., Weiss, M., Hauschildt, S., Hecker, T. K., Luzzio, F. A., Eger, K., & Figg, W. D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0304820 · Cited by 51
Cox-2 Inhibitors: Today and Tomorrow
McMurray, R. W., & Hardy, K. J. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200204000-00003 · Cited by 50
α-Fluoro-substituted thalidomide analogues
Man, H., Corral, L. G., Stirling, D., & Muller, G. W. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00778-9 · Cited by 50
Genomics and the second golden era of cancer drug development
Workman, P. (2005) · Molecular BioSystems · doi:10.1039/b501751n · Cited by 49
Future potential of thymidylate synthase inhibitors in cancer therapy
Lehman, N. L. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1775 · Cited by 48
Vema, A., Rambabu, G., Panigrahi, S. K., Sarma, J. A. R. P., & Desiraju, G. R. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049676u · Cited by 48
Antibiotic resistance: multidrug efflux proteins, a common transport mechanism?
Langton, K. P., Henderson, P. J. F., & Herbert, R. B. (2005) · Natural Product Reports · doi:10.1039/b413734p · Cited by 46
Synthesis, Characterization and Biological Evaluation of 7α-Perfluoroalkylestradiol Derivatives
Blazejewski, J., Wilmshurst, M. P., Popkin, M. D., Wakselman, C., Laurent, G., Nonclercq, D., Cleeren, A., Ma, Y., Seo, H.-S., & Leclercq, G. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00457-1 · Cited by 44
Wang, S., Wan, N. C., Harrison, J., Miller, W., Chuckowree, I., Sohal, S., Hancox, T. C., Baker, S. J., Folkes, A. J., Wilson, F. X., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0310129 · Cited by 44
Lévy-Piedbois, C., Durand‐Zaleski, I., Juhel, H., Schmitt, C. A., Bellanger, A., & Piedbois, P. (2000) · Annals of Oncology · doi:10.1023/a:1008358411251 · Cited by 42
Emanuel, S. L., Gruninger, R. H., Fuentes‐Pesquera, A. R., Connolly, P. J., Seamon, J. A., Hazel, S. J., Tominovich, R. M., Hollister, B. A., Napier, C., D’Andrea, M. R., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.000638 · Cited by 41
New Dermatological Agents for the Treatment of Psoriasis
Thacher, S. M., Vasudevan, J., Tsang, K.-Y., Nagpal, S., & Chandraratna, R. A. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0000214 · Cited by 41
Mozziconacci, J., Arnoult, É., Bernard, P., Do, Q. T., Marot, C., & Morin‐Allory, L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049332v · Cited by 40
SERMs in chemoprevention of breast cancer
Gasco, M., Argusti, A., Bonanni, B., & DeCensi, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.017 · Cited by 36
Hermenegildo, C., & Cano, A. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.237 · Cited by 34
Prostate cancer PET bioprobes: Synthesis of [18F]-radiolabeled hydroxyflutamide derivatives
Jacobson, O., Bechor, Y., Icar, A., Novak, N., Birman, A., Marom, H., Fadeeva, L., Golan, E., Leibovitch, I., Gutman, M., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.06.033 · Cited by 32
Liu, Y., Ahmed, V. F., Hill, B., & Taylor, S. D. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b508852f · Cited by 28
New cancer therapeutics: target-specific in, cytotoxics out?
Broxterman, H. J., & Georgopapadakou, N. H. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.02.004 · Cited by 22
Anti-oestrogenic chemoprevention of breast cancer—the need to progress
Powles, T. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00771-2 · Cited by 21
Smith, D. B., & Gallagher, N. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00271-5 · Cited by 21
Pharmacology of Fluorinated Pyrimidines: Eniluracil
Baker, S. D. (2000) · Investigational New Drugs · doi:10.1023/a:1006453500629 · Cited by 20
Seimbille, Y., Bénard, F., & van Lier, J. E. (2002) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/b205571f · Cited by 18
Phosphoramidite approach for the synthesis of cardiolipin1See Ref. 1.1
Krishna, U. M., Ahmad, M. U., & Ahmad, I. (2004) · Tetrahedron Letters · doi:10.1016/j.tetlet.2004.01.072 · Cited by 12
Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world?
Piccart, M. J., & Loi, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.09.019 · Cited by 3
Research works printed but not linked: 67
- Danenberg, 2004, Frontiers Biosci., 9, 2484, 10.2741/1410 · doi:10.2741/1410
- Peters, 2002, Biochem. Biophys. Acta, 1587, 194
- Punt, 1998, Cancer, 83, 679, 10.1002/(SICI)1097-0142(19980815)83:4<679::AID-CNCR8>3.0.CO;2-F · doi:10.1002/(sici)1097-0142(19980815)83:4<679::aid-cncr8>3.0.co;2-f
- Petty, 2004, Curr. Cancer Drug Targets, 4, 191, 10.2174/1568009043481533 · doi:10.2174/1568009043481533
- Feliu, 2004, Br. J. Cancer, 91, 1758, 10.1038/sj.bjc.6602217 · doi:10.1038/sj.bjc.6602217
- Shirasaka, 1996, Cancer Res., 56, 2602
- Xu, 2001, Clin. Cancer Res., 7, 3314
- Cooke, 2001, Org. Process. Res. Dev., 5, 383, 10.1021/op0100100 · doi:10.1021/op0100100
- Kalman, 2000, Biorg. Med. Chem. Lett., 10, 391, 10.1016/S0960-894X(00)00012-3 · doi:10.1016/s0960-894x(00)00012-3
- Kalman, 2001, Nucleosides Nucleotides, 20, 869, 10.1081/NCN-100002448 · doi:10.1081/ncn-100002448
- Tanabe, 2005, Biorg. Med. Chem. Lett., 15, 2321, 10.1016/j.bmcl.2005.03.013 · doi:10.1016/j.bmcl.2005.03.013
- Herrlinger, 2005, Pharm. Genomics, 15, 2005
- Jackman, 2002, Biochim. Biophys. Acta, 1587, 215, 10.1016/S0925-4439(02)00084-4 · doi:10.1016/s0925-4439(02)00084-4
- Foss, 2004, Best Pract. Res. Clin. Hematol., 17, 573, 10.1016/S1521-6926(04)00075-1 · doi:10.1016/s1521-6926(04)00075-1
- Cataland, 2001, Curr. Pharm. Biotechnol., 2, 357, 10.2174/1389201013378608 · doi:10.2174/1389201013378608
- Brackwitz, 1999, Biorg. Chem. Med. Lett., 7, 1195, 10.1016/S0968-0896(99)00027-9 · doi:10.1016/s0968-0896(99)00027-9
- Bauta, 2004, Org. Process. Res. Dev., 8, 889, 10.1021/op049884n · doi:10.1021/op049884n
- Pourquier, 2002, Clin. Cancer Res., 8, 2499
- Jiang, 2000, Cancer Chem. Pharm., 45, 320, 10.1007/s002800050047 · doi:10.1007/s002800050047
- Walkins, 2005, Curr. Pharm. Des., 11, 1615, 10.2174/1381612053764742 · doi:10.2174/1381612053764742
- Nicolaou, 1998, Angew. Chem. Int. Ed., 37, 1418, 10.1002/(SICI)1521-3773(19980605)37:10<1418::AID-ANIE1418>3.0.CO;2-5 · doi:10.1002/(sici)1521-3773(19980605)37:10<1418::aid-anie1418>3.0.co;2-5
- Honore, 2003, Mol. Cancer Ther., 2, 1303
- Mooberry, 1999, Cancer Res., 59, 653
- Hood, 2002, Cancer Res., 62, 3356
- Gao, 2005, Biorg. Med. Chem. Lett., 15, 3233, 10.1016/j.bmcl.2005.04.063 · doi:10.1016/j.bmcl.2005.04.063
- Zunino, 1990, Anticancer Drug Des., 5, 307
- Giannini, 2004, Med. Chem. Rev., 1, 47
- Xia, 2001, J. Med. Chem., 44, 3932, 10.1021/jm0101085 · doi:10.1021/jm0101085
- Rubin, 2002, Clin. Cancer Res., 8, 3710
- Stüdemann, 1997, Tetrahedron, 54, 1229
- Stüdemann, 1997, Angew. Chem. Int. Ed. Engl., 36, 93, 10.1002/anie.199700931 · doi:10.1002/anie.199700931
- Pasqualini, 2004, Biochimica Biophys. Acta, 1654, 123
- Konno, 2004, Org. Lett., 6, 933, 10.1021/ol036440n · doi:10.1021/ol036440n
- Robertson, 2005, Eur. J. Cancer, 41, 346, 10.1016/j.ejca.2004.07.035 · doi:10.1016/j.ejca.2004.07.035
- Howell, 2004, Eur. J. Cancer, 9, 65
- Dodwell, 2005, Cancer Treatment Rev., 31, 274, 10.1016/j.ctrv.2005.03.009 · doi:10.1016/j.ctrv.2005.03.009
- de Velde, 1995, Ann. N.Y. Acad. Sci., 761, 164, 10.1111/j.1749-6632.1995.tb31377.x · doi:10.1111/j.1749-6632.1995.tb31377.x
- Jordan, 2003, J. Med. Chem., 46, 893
- Giannoukos, 2001, Mol. Endocrinol., 15, 255, 10.1210/me.15.2.255 · doi:10.1210/me.15.2.255
- Cleve, 2005, J. Fluorine Chem., 126, 217, 10.1016/j.jfluchem.2004.08.004 · doi:10.1016/j.jfluchem.2004.08.004
- Noble, 2004, Drug Discov., 303, 1800
- Matushansky, 2005, Am. Scientist, 93, 414, 10.1511/2005.55.972 · doi:10.1511/2005.55.972
- Alberti, 2005, Birog. Med. Chem. Lett., 15, 3778, 10.1016/j.bmcl.2005.05.100 · doi:10.1016/j.bmcl.2005.05.100
- Cockerill, 2002, Curr. Top. Med. Chem., 2, 1001, 10.2174/1568026023393309 · doi:10.2174/1568026023393309
- Herbst, 2004, Int. J. Radiat. Oncol. Biol. Phys., 59, 21, 10.1016/j.ijrobp.2003.10.027 · doi:10.1016/j.ijrobp.2003.10.027
- Pandey, 2003, World J. Surg. Oncol., 1, 9, 10.1186/1477-7819-1-9 · doi:10.1186/1477-7819-1-9
- Bell, 2004, J. Med. Chem., 47, 1869, 10.1021/jm0305467 · doi:10.1021/jm0305467
- Piatnitski, 2005, Biorg. Med. Chem. Lett., 15, 4696, 10.1016/j.bmcl.2005.07.064 · doi:10.1016/j.bmcl.2005.07.064
- Gingrich, 2003, J. Med. Chem., 46, 5375, 10.1021/jm0301641 · doi:10.1021/jm0301641
- Fink, 2005, Biorg. Med. Chem., 15, 4774, 10.1016/j.bmcl.2005.07.027 · doi:10.1016/j.bmcl.2005.07.027
- Ahn, 2005, Science, 308, 1266, 10.1126/science.1113707 · doi:10.1126/science.1113707
- Nair, 2004, Tetrahedron Lett., 45, 9475, 10.1016/j.tetlet.2004.10.130 · doi:10.1016/j.tetlet.2004.10.130
- Sani, 2005, Lett. Org. Chem., 2, 447, 10.2174/1570178054405850 · doi:10.2174/1570178054405850
- Barker, 2005, J. Med. Chem., 48, 4507, 10.1021/jm050345y · doi:10.1021/jm050345y
- Kankaaranta, 1995, Mol. Pharmacol., 47, 1006
- Armer, 2005, J. Med. Chem., 48, 6174, 10.1021/jm050519b · doi:10.1021/jm050519b
- Goldman, 2002, Formulary, 37, 68
- Schedler, 2004, Carbohydr. Res., 339, 1585, 10.1016/j.carres.2004.03.030 · doi:10.1016/j.carres.2004.03.030
- El-Kabbani, 2005, J. Med. Chem., 48, 5536, 10.1021/jm050412o · DOI
- Whitehead, 2005, J. Med. Chem., 48, 1237, 10.1021/jm030603w · doi:10.1021/jm030603w
- Guo, 2005, Biorg. Med. Chem. Lett., 15, 3685, 10.1016/j.bmcl.2005.05.038 · doi:10.1016/j.bmcl.2005.05.038
- Gründker, 2000, Gynecol. Oncol., 78, 194, 10.1006/gyno.2000.5863 · doi:10.1006/gyno.2000.5863
- Kunkel, 2003, Cancer, 98, 2257, 10.1002/cncr.11763 · doi:10.1002/cncr.11763
- Toyokuni, 2005, Biorg. Med. Chem. Lett., 15, 4699, 10.1016/j.bmcl.2005.07.065 · doi:10.1016/j.bmcl.2005.07.065
- Wang, 2005, Biorg. Med. Chem. Lett., 15, 4380, 10.1016/j.bmcl.2005.06.038 · doi:10.1016/j.bmcl.2005.06.038
- Cui, 2004, Magn. Resonance Med., 51, 616, 10.1002/mrm.10719 · doi:10.1002/mrm.10719
- Yu, 2004, Bioconjug. Chem., 15, 1334, 10.1021/bc049936d · doi:10.1021/bc049936d
Cited by
Fluorine in Pharmaceuticals: Looking Beyond Intuition
Müller, K., Faeh, C., & Diederich, F. (2007) · Science · doi:10.1126/science.1131943 · Cited by 6,596
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Introduction of Fluorine and Fluorine‐Containing Functional Groups
Liang, T., Neumann, C. N., & Ritter, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201206566 · Cited by 2,564
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
Metadata
- Authors
- Isanbor, C., & O’Hagan, D.
- Venue
- Journal of Fluorine Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 127
- Issue
- 3
- Pages
- 303-319
- ISSN
- 0022-1139 (ISSN-L)
- OpenAlex
- W2174657615
- Cited by
- 1,120
- References
- 104
- FWCI
- 26.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.